SB 202190

SB 202190 is a selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38? (SAPK2A, MAPK14) and p38? (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively.{21464,12847} When tested at 10 ?M, SB 202190 has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs).{12847} Pyridinyl imidazole inhibitors, including this compound, directly bind p38 MAP kinases in the ATP binding pocket.{15221} Recently, SB 202190 has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine-induced receptor expression, and HIV-mediated depressive disorder.{21463,21466,21467}